For Washington employers, pharmacy costs can rise quickly when a medication class moves from a specialized treatment to a widely requested benefit. GLP-1 medications were originally approved for Type 2 diabetes and are now widely used for chronic weight management, increasing attention from CFOs and HR leaders evaluating plan design.
The financial pressure from GLP-1 weight loss drugs employer health plans is showing up in pharmacy trend first, driven by both high per-member costs and growing utilization. The right response is not automatically to remove coverage, but to pair thoughtful access with clinical oversight, transparent pharmacy-benefit management, and a broader weight-management strategy.
Washington Health Insurance Agency (WHIA) helps employers examine those decisions in the context of their workforce, plan goals, and claims data. First, it helps to understand what these medications do and why they have become such a significant employer health plan issue.
What GLP-1 Drugs Do and Why Employer Health Plans Are Paying Attention
GLP-1 drugs are a class of prescription medications that affect appetite and blood sugar regulation. Ozempic and Mounjaro were developed and approved for Type 2 diabetes, while Wegovy and Zepbound were later approved for chronic weight management. They are related medications, but they do not all carry the same approved indications, dosing schedules, or coverage rules.
These medications mimic a hormone that helps signal fullness to the brain, which can reduce appetite and food intake. That mechanism helps explain both their clinical interest and the growing number of employees asking whether their employer health plan covers them. GLP-1 medications are not a short-term wellness trend. Obesity is a chronic condition that may require ongoing management, so coverage decisions can affect pharmacy spending over multiple plan years.
Why GLP-1 demand exploded
Demand has expanded beyond traditional diabetes treatment as more people and clinicians consider GLP-1 medications for chronic weight management. Employers are seeing that change directly through employee questions, benefits discussions, and requests for clearer coverage information. Washington employer groups, in particular, are reporting an uptick in inquiries about including GLP-1s in their health plans.
For CFOs and HR directors, the issue is not simply whether a medication is popular. It is how rising demand interacts with pharmacy benefit design, clinical eligibility, employee access, and the plan's broader cost trend. High-cost medications can put pressure on pharmacy spending as utilization grows, even when only a portion of the workforce uses them. That makes it important to understand what the drugs do before deciding how they should fit into the benefit strategy.
The practical question for employers is how to balance medically appropriate access with a sustainable, clearly communicated benefit. That requires looking beyond a yes-or-no coverage decision and examining the plan's clinical protocols, formulary, and pharmacy management approach.
Why GLP-1 Weight Loss Drugs Are Driving Up Employer Health Plan Costs
The financial pressure from GLP-1 medications is not caused by one factor. It comes from the combination of a high cost per member per month and rapidly increasing utilization. When more employees qualify for treatment, even a well-designed employer health plan can see pharmacy spending rise quickly. That makes GLP-1 weight loss drugs a material consideration for employer health plans, not simply a temporary prescription trend.
The scale of the market helps explain why employers are paying closer attention. According to UnitedHealthcare, net U.S. spending on the drug class increased from $13.7 billion in 2018 to $71.7 billion in 2023, an increase of more than 500%. Net spending reflects the amount paid after discounts and rebates, so the trend represents substantial growth in actual drug expenditure across the healthcare system.
Utilization pressure may continue as coverage decisions expand. The Peterson-KFF Health System Tracker reports that 34% of non-elderly people with employer-sponsored insurance, or approximately 36.2 million people, have a body mass index that medically qualifies them for a GLP-1 medication. Qualification does not mean every person will seek treatment or receive coverage. It does show why employers need to evaluate potential demand rather than budget only for current utilization.
For CFOs and HR leaders, the practical issue is the interaction between eligibility, prescribing, duration of treatment, and plan design. A medication with a high per-member-per-month cost can create meaningful budget impact when utilization grows. Particularly if the plan does not distinguish clinical eligibility, ongoing follow-up, and appropriate continuation of therapy. Employers also need to consider how pharmacy claims affect renewals and overall health plan strategy.
This is not an argument for removing access or treating every prescription as inappropriate. It is a reason to examine the underlying claims data, coverage rules, and clinical management approach together. A clear view of the cost drivers gives an employer more options than reacting to a renewal increase after the fact.
How Employers Are Covering GLP-1s Today: Diabetes, Obesity, and Everything Between
There is no single standard for covering GLP-1 medications in an employer health plan. The drugs were first approved for Type 2 diabetes, so many plans began by covering them for diabetes-related indications. Coverage for chronic weight management developed later and is still far less consistent. That distinction matters for employers reviewing both employee access and pharmacy spending.
Why coverage varies from plan to plan
Plan design, carrier rules, pharmacy benefit manager policies, and an employer's approach to utilization management all shape the outcome. A plan may cover GLP-1s for Type 2 diabetes while excluding weight-management indications. Another may cover obesity treatment, but only when an employee meets clinical requirements such as a stated body mass index threshold or has a related health condition. Some plans also require prior authorization, which means a clinician must document that the member meets the plan's criteria before the prescription is approved.
Weight-management coverage may also be tied to a concurrent lifestyle or clinical program. These requirements can include nutrition support, behavioral coaching, regular follow-up, or documentation that other treatment approaches were considered. The goal is not simply to approve or deny a medication. It is to create a clear, clinically grounded process that employees and their physicians can understand.
Industry surveys show how uneven the landscape remains. One 2025 survey of employer plans reported that 87% provided some GLP-1 coverage. Within that group, 35% covered the medications for diabetes only, 23% covered obesity along with cardiovascular risk, and 29% offered comprehensive coverage across conditions. The survey also found that 12% of plans provided no coverage, although many of those employers were considering adding it within 12 to 24 months. These figures are useful context, not a universal benchmark for every Washington employer.
| Coverage approach | What it typically includes | Share of surveyed plans |
|---|---|---|
| Diabetes only | GLP-1s covered when prescribed for Type 2 diabetes; weight-management indications excluded | 35% |
| Obesity plus cardiovascular risk | Weight-management coverage with defined clinical criteria, including related conditions | 23% |
| Comprehensive | Coverage across diabetes, obesity, and cardiovascular indications | 29% |
| No coverage | No GLP-1 coverage, though many of these plans are evaluating adding it within 12 to 24 months | 12% |
Washington employer groups are already seeing more employee and leadership inquiries about including GLP-1s in their benefit plans. Before changing a plan, employers should review the eligibility rules, authorization process, exclusions, and financial impact together. A shift in prescription formulary changes can affect employee expectations, prescriber workflows, and the plan's pharmacy trend, so the communication strategy matters as much as the coverage decision.
Smart Ways to Manage GLP-1 Pharmacy Costs Without Slashing Benefits
Employers do not have to choose between unrestricted spending and removing meaningful access to treatment. A better approach is to manage how coverage is designed, administered, and supported. The goal is to apply clinically appropriate guardrails, improve visibility into pharmacy arrangements, and give employees a clearer path to effective care.
The management toolkit
- Use clinical prior authorization. Require documentation that a prescription meets defined clinical criteria, such as a relevant BMI threshold plus a weight-related comorbidity, while keeping the review process consistent and understandable. Prior authorization should confirm medical appropriateness, not create an arbitrary barrier to care.
- Apply step therapy when clinically appropriate. A plan may ask a member to try a lower-cost treatment option before moving to a higher-cost medication. The protocol should include reasonable exceptions when a lower-cost option is not appropriate for the member's clinical situation.
- Review formulary tiering. The formulary determines how medications are grouped and what members and the plan pay. Thoughtful tier placement, coverage rules, and regular review can help align plan spending with clinical value without treating every GLP-1 prescription the same way.
- Consider a transparent PBM carve-out. Separating pharmacy benefit management from the broader health plan can make pricing, rebates, dispensing fees, and administrative charges easier to evaluate. Employers exploring this route can review transparent PBM pharmacy cost management and learn more about how pharmacy benefit management works.
- Pair coverage with clinical care management. Interdisciplinary weight management programs can connect members with coordinated support from appropriate professionals, rather than treating medication as an isolated pharmacy expense. One study found that combining anti-obesity medication with an employer-based interdisciplinary weight management program produced clinically superior weight loss compared with the program alone. The published study can help employers evaluate the evidence behind an integrated approach.
These tools work best as a coordinated strategy. Prior authorization and step therapy address appropriate utilization, formulary design and PBM transparency address the financial mechanics, and clinical care management supports better health outcomes. Together, they can help employers manage pharmacy trend while preserving benefits that employees may genuinely need.
How Washington Health Insurance Agency Helps Employers Manage Pharmacy Trend
For Washington employers, the right response to rising GLP-1 pharmacy costs is not a blanket decision to remove coverage. It is a clearer view of what the plan is paying for. How utilization is managed, and whether the pharmacy benefit manager (PBM) contract aligns with the employer's interests. Washington Health Insurance Agency (WHIA) starts with a pharmacy cost audit so employers can make decisions from their own plan data rather than from a generic market promise.
Start with the contract and the claims data
WHIA operates as a wholesaler and aggregator with direct carrier partnerships and purchasing power. That model gives the team a broader view of plan design and pharmacy economics than a conventional product-placement conversation. The first step is to examine the PBM arrangement for pricing terms, incentives. Rebate treatment, and provisions that may be difficult for an employer to see without specialized review. Employers can also use transparent pharmacy contracts as a reference point when evaluating whether their current arrangement provides meaningful visibility.
Claims data analysis adds the operational context. WHIA can assess pharmacy spending, utilization patterns, member eligibility, and the way high-cost medications are affecting the overall trend. That does not mean identifying individual employees or questioning clinically appropriate care. It means giving the employer a practical picture of where plan dollars are going and which management decisions deserve attention. A focused claims data analysis can help separate a broad cost trend from a specific benefit-design or utilization issue.
Balance access, oversight, and advocacy
WHIA helps employers balance medication access with cost-containment measures such as prior authorization, formulary strategy, and managed weight-loss support. The goal is not to treat every GLP-1 prescription the same or to substitute an insurance rule for a physician's judgment. Instead, the employer can evaluate whether the plan's clinical protocols are understandable, consistently administered, and connected to an overall benefits strategy.
Throughout the process, WHIA acts as an advocate for the employer. The team can translate PBM and carrier language, identify questions for renewal discussions, and help leadership weigh employee access against cost predictability. This white-glove approach is part of How We're Different: employers receive analysis and guidance designed around their workforce, not a one-size-fits-all pharmacy recommendation.
Frequently Asked Questions
What health insurance companies cover GLP-1 drugs?
Many major insurers offer some GLP-1 coverage, but the employer's plan design determines whether a prescription is covered for diabetes, obesity, cardiovascular risk, or another indication. The carrier name alone does not answer the question. Employers should review the formulary, prior authorization rules, eligibility criteria, and exclusions that apply to their specific group plan.
Why are employers not covering GLP-1 drugs?
The primary concern is cost and the potential effect on premiums. These medications can cost more than $1,000 per month before rebates. And U.S. net spending on the drug class increased from $13.7 billion in 2018 to $71.7 billion in 2023, an increase of more than 500% (UnitedHealthcare). Some employers therefore evaluate coverage conditions and clinical safeguards before expanding access.
Do employer health plans cover GLP-1 drugs for obesity, not just diabetes?
Some do, but coverage remains uneven. A plan may cover GLP-1 medications for Type 2 diabetes while excluding weight-management treatment, or it may cover obesity treatment under defined clinical criteria. Employers should confirm the indication-specific language in their plan documents and ask how any coverage change would affect employees and dependents.
What strategies can employers use to manage GLP-1 pharmacy costs?
Employers can combine coverage with prior authorization based on clinical criteria, step therapy, formulary tiering, transparent pharmacy benefit management, and ongoing clinical care management. Reviewing claims data and coordinating medication support with broader weight-management programs can help manage utilization while preserving access for members who meet the plan's requirements.
Ready to review your GLP-1 strategy?
GLP-1 coverage decisions can affect both employee access and the direction of your pharmacy trend. Washington Health Insurance Agency (WHIA) can review your current approach and identify practical questions to bring into your next renewal discussion. Contact WHIA at 360-464-1622 to schedule a pharmacy cost audit and discuss your next steps.